Bayer’s Legal and Financial Reckoning Nears a Climax

The coming days represent a defining moment for Bayer AG as two pivotal events converge, threatening to either cap a multi-billion euro legal saga or extend the uncertainty that has shadowed the company for years. While its stock has staged a remarkable recovery, gaining roughly 90% from its April 2025 low of €21.66 to trade around €40.60 on Tuesday, the immediate future hinges on a critical legal argument and a key shareholder meeting.

At the core of the company’s troubles is the legacy of its Monsanto acquisition, which has so far generated costs exceeding €24 billion over seven years. These figures encompass settlements, compensation, and legal advisory fees. In February, Bayer set aside an additional €6.7 billion, and negotiations continue for a further settlement of around $7.5 billion for remaining litigation complexes. The Trump administration’s recent support for Bayer’s legal position, reversing the stance of the previous U.S. government, offers a surprising tailwind.

The most consequential event is scheduled for Monday, April 27, when the U.S. Supreme Court hears oral arguments in the Durnell case. Bayer’s defense rests on the principle of “preemption,” arguing that federal law (FIFRA) overrides state-level requirements for cancer warning labels on its Roundup herbicide. A favorable ruling could strip tens of thousands of pending lawsuits of their legal foundation, a prospect that has kept investors and analysts on edge. Previous lower courts have largely rejected this argument.

Just three days prior, on Friday, April 24, management will host a virtual Annual General Meeting. Shareholders are set to vote on a minimal dividend of €0.11 per share and oversee a supervisory board reshuffle, with Marcel Smits and Alfred Stern replacing Paul Achleitner and Colleen Goggins. CEO Bill Anderson, in a pre-released speech, will emphasize the company’s transformation, stating that no part of the conglomerate exists in its original form following significant delayering and restructuring.

Should investors sell immediately? Or is it worth buying Bayer?

Operationally, Bayer’s pharmaceutical division is delivering strong performance. Its kidney and heart drug Kerendia recently posted currency-adjusted growth of 88%, with the company targeting peak sales exceeding €3 billion. Another pipeline hope, the anticoagulant Asundexian, showed promise in a pivotal study of over 12,000 patients, reducing stroke risk by 26%. The drug has already received Fast Track designation from the U.S. FDA.

Financially, the company’s net financial debt decreased by 8.5% to just under €29.8 billion. However, free cash flow is under significant pressure this year, with management anticipating outflows of approximately €5 billion for glyphosate settlements alone. Analysts, on average, expect earnings of €4.29 per share for 2026.

Technically, the stock appears oversold, with its Relative Strength Index (RSI) at a low level of 23. If support around €40.20 holds, the next resistance level to watch is €43.90. The calendar remains packed, with first-quarter results due on May 12 and a June 4 deadline for claimants to opt out of a nationwide settlement. A final Supreme Court decision is expected by summer, potentially providing the clarity Bayer needs to finally close its most significant financial wound.